当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2009年第1期 > 正文
编号:11727989
痰热清注射液配合常规疗法治疗COPD急性发作的疗效观察(1)
http://www.100md.com 2009年1月5日 陈石桥
第1页

    参见附件(1063KB,2页)。

     [摘要] 目的:探讨痰热清注射液配合常规疗法治疗慢性阻塞性肺疾病(COPD)急性发作的疗效及其可能的作用机制。方法:102例COPD急性发作期患者随机分为常规疗法组和联用痰热清治疗组;联用痰热清治疗组在常规疗法的基础上联用痰热清注射液治疗。观察两组临床疗效、症状积分及血气分析结果。结果:联用痰热清治疗组显效率为72.55%,常规疗法组为58.82%,差异有显著性(P<0.05)。治疗后联用痰热清治疗组患者症状积分及血气分析结果均明显优于常规组(P<0.05)。结论:在常规疗法的基础上联用痰热清注射液治疗COPD急性发作能明显提高临床疗效,这可能与痰热清注射液对多种病原菌均有较好的抑制作用,减少内毒素产生,进而减轻COPD的炎症过程有关。

    [关键词] 慢性阻塞性肺疾病;痰热清注射液;临床疗效

    [中图分类号] R563 [文献标识码]B[文章编号]1673-7211(2009)01(a)-088-02

    Effect of Tanreqing Injections in acute chronic obstructive pulmonary disease

    CHEN Shi-qiao

    (Department of Internal Medicine,Songgang Hospital of Nanhai,Foshan 528234,China)

    [Abstract] Objective: To observethe effects of treatment with Tanreqing injections combined with routine methods in acute COPD and study the mechanism of action. Methods: 102 patients with COPD were divided into two groups randomly. In the combined group, we added Tanreqing injections in the treatment.We observedthe effects of treatment and symptom integral and blood gas analysis of patients. Results: The combined group's effective rate was 72.55%, routine methods group was 58.82%. Difference was apparent (P<0.05). The levels of symptom integral and blood gas analysis in combined group was significantly excel than routine group (P<0.05)after treatment. Conclusion: On the basis of routine treatment combined with Tanreqing injections can heighten the curative effect in COPD. It's concern with that Tanreqing could depressed markedly multitude of pathogenic bacterium, lighten production of endotoxin and lessen inflammation of COPD.

    [Key words] COPD; Tanreqing injections; Curative effect

    慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)是一种具有气流受限特征的疾病,气流受限不完全可逆,呈进行性发展,与肺部对有害气体或有害颗粒的异常炎症反应有关[1]。多种病原菌的感染及内毒素的产生,参与COPD的炎症过程已引起众多学者的关注[2]。近年来有研究发现痰热清注射液具有抗菌、抗炎、抗病毒、解热、化痰、止咳作用而应用于多种疾病的治疗[3]。本研究观察痰热清注射液配合常规疗法治疗COPD急性发作的疗效并初步探讨其作用机制。

    1资料与方法

    1.1一般资料

    选取102例于2006年6月~2007年6月在我院住院的COPD患者, 男66例,女36例;年龄49~88岁,平均(63.5±6.6)岁;所有病例均符合中华医学会呼吸病学分会慢性阻塞性肺疾病学组2007年修订的《慢性阻塞性肺疾病诊治指南》中的诊断标准[1]。病例随机分为常规疗法组(51例)和联用痰热清治疗组(51例),两组在性别、年龄、病史等方面无显著性差异(P>0.05),具有可比性。

    1.2治疗方法

    均给予抗生素静脉滴注、解痉平喘、氧疗,合并心衰者予以强心利尿等治疗。联用痰热清治疗组在上述治疗的基础上联用国产的痰热清注射液20~30 ml,加入5%葡萄糖或0.9%氯化钠注射液中静脉滴注 ......

您现在查看是摘要介绍页,详见PDF附件(1063KB,2页)